James O. Armitage MD and Hagop M. Kantarjian MD on Advances in the Treatment of ALL

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center and the University of South Florida, and James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, discuss the biology and diagnostic criteria for myelodysplastic syndrome, as well as advances in the disease presented at the 56th ASH Annual Meeting.

Lymphoma

Bertrand Coiffier, MD

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504, “Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association With CHOP in Patients With Peripheral T-Cell Lymphoma (PTCL)” presented by Jehan Dupuis, MD.

Time: 1:53

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on the UK NCRI AML17 Trial

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7, “A Randomized Comparison of Daunorubicin 90 mg/m² vs 60 mg/m² in AML Induction: Results From the UK NCRI AML17 Trial in 1206 Patients,” presented by Alan K. Burnett, MD.

Time: 1:29

Lymphoma

Myelodysplastic Syndromes

Richard M. Stone, MD

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117,” presented by Mikkael A. Sekeres, MD, MS.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

Related Videos

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Richard M. Stone, MD, on the UK NCRI AML17 Trial

Richard M. Stone, MD, on the SWOG S1117 Study

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

World Cancer Day 2026 UICCs Campaign United by Unique

Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer

American College of Surgeons Publishes Annual NCDB Report